SOURCE: Barrier Therapeutics, Inc.

January 03, 2007 15:30 ET

Barrier Therapeutics to Present at the 25th Annual JPMorgan Healthcare Conference

PRINCETON, NJ -- (MARKET WIRE) -- January 3, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Geert Cauwenbergh, Ph.D., Chief Executive Officer, and Al Altomari, Chief Operating Officer, are scheduled to provide a company update at the 25th Annual JPMorgan Healthcare Conference.

The conference will be held at the Westin St. Francis in San Francisco on January 8-11, 2007. Barrier Therapeutics is scheduled to present on Tuesday, January 9 at 3:00 p.m. PST (6:00 p.m. EST).

The presentation will be available live via a webcast and can be accessed through the Investor Relations section of Barrier Therapeutics' corporate website at: An archive of the presentation will be available for replay until April 9, 2007.

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including acne, psoriasis, onychomycosis and other fungal infections such as tinea versicolor. The company is headquartered in Princeton, New Jersey and has wholly-owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at:

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent